GlaxoSmithKline has decided to keep its cephalosporins antibiotics business but reorganize it to be more efficient, cutting nearly 200 jobs at its Ulverston site in the U.K. More: GSK to hold on to its antibiotics business, but nearly 200 workers
read moreBoehringer Ingelheim and Eli Lilly’s Tradjenta is working to pick up share in an ultracompetitive diabetes market, and it’s hoping some new outcomes data can help it do exactly that. More: Lilly, Boehringer hit heart safety mark with Januvia rival
read moreThe highly anticipated Medical & Scientific Excellence Awards close for entry in just a few weeks (31 October). This is your chance to stand out against the competition, enter now to get the recognition you deserve. More: Demonstrate your skills and expertise Source: News
read moreGilead Sciences has one-upped Novartis in England’s CAR-T market. After a NICE rejection up front, the drugmaker has cut a discount deal with NHS England on Yescarta, beating rival Kymriah to become the first CAR-T therapy available to adult lymphoma
read moreThe Medicines and Healthcare products Regulatory Agency has launched a consultation seeking views on how its legislation and regulatory processes would have to be modified if the UK leaves the EU under a ‘no-deal’ scenario. More: MHRA consults on new
read moreRoche’s Hemlibra has been approved in the US for routine prophylaxis of bleeding episodes patients with haemophilia A without factor VIII inhibitors. More: Use of Roche’s haemophilia A therapy Hemlibra expanded in the US Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals